Humacyte (HUMA): Benchmark Remains Bullish on Stock

Humacyte, Inc. (NASDAQ:HUMA) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

In mid-November, Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte, Inc. (NASDAQ:HUMA) stock and set a price target of $11. Humacyte, Inc. (NASDAQ:HUMA) engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Humacyte, Inc. (NASDAQ:HUMA) recently announced that it had entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60 million worth of its common stock and warrants in an oversubscribed registered direct offering. The warrants will become exercisable 180 days following the date of issuance and have an exercise price of $2.11 per share.

While we acknowledge the potential of HUMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term